GENE ONLINE|News &
Picard Medical and SynCardia Systems Complete Preclinical Implant Studies for Emperor Total Artificial Heart
Picard Medical and its subsidiary, SynCardia Systems, completed a series of preclinical implant studies for the next-generation Emperor Total Artificial Heart (TAH) on June 2, 2026. The research team evaluated the performance and integration of the new device, marking a progression in the company’s ongoing development program for mechanical circulatory support technology.
The preclinical trials focused on testing the mechanical functionality and physiological compatibility of the Emperor TAH within a controlled environment. These studies serve as a technical milestone for the company as it works to refine the device’s design and operational capabilities. Picard Medical and SynCardia intend to use the data gathered from these procedures to inform future development phases and regulatory submissions. The companies have not yet announced a timeline for human clinical trials or final commercial availability.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: June 2, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Insilico Medicine’s ISM8969 Enters Phase 1 Trial, Advancing Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation and CNS Disorders
2026-06-18
ArcelorMittal, thyssenkrupp, and voestalpine Call for EU Emissions Trading System Reforms to Protect Steel Competitiveness
2026-06-18
Six Taipei Biotechs Head to BIO 2026 in San Diego, With Precision Medicine, Drug Delivery, and Bioprocess Innovation in Focus
2026-06-18
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
